L-R He1, H-Y Zhao2, B-K Li3, L-J Zhang3, M-Z Liu4, H-F Kung5, X-Y Guan5, X-W Bian6, Y-X Zeng5, D Xie7. 1. State Key Laboratory of Oncology in South China; Department of Radiotherapy. 2. Department of Medical Oncology. 3. Department of Surgical Oncology, Cancer Center, Sun Yat-Sen University, Guangzhou. 4. Department of Radiotherapy. 5. State Key Laboratory of Oncology in South China. 6. Department of Pathology, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China. 7. State Key Laboratory of Oncology in South China. Electronic address: xied@mail.sysu.edu.cn.
Abstract
BACKGROUND: The amplified in breast cancer 1 (AIB1) gene has been considered to play an oncogenic role in human cancers, but its clinical/prognostic significance in non-small-cell lung cancer (NSCLC) is still unclear. PATIENTS AND METHODS: The methods of immunohistochemistry and FISH were utilized to examine protein expression and amplification of AIB1 in 230 informative surgically resected NSCLCs and in 30 samples of normal lung tissues. RESULTS: Overexpression and amplification of AIB1 were found in 48.3% and 8.2% of NSCLCs, respectively. AIB1 overexpression was associated with AIB1 gene amplification and cell proliferation but not related to estrogen receptor (ER)-alpha, ER-beta, progesterone receptor or androgen receptor status. A positive correlation between AIB1 overexpression and an ascending pathologic node stage in lung adenocarcinoma (ADC) was observed (P = 0.043). Univariate survival analysis demonstrated a significant association of AIB1 overexpression with shortened patient survival, especially for those with stage III disease (P < 0.001). Importantly, AIB1 expression was evaluated as the most significant predictor for survival in multivariate analysis (hazards ratio = 2.069, P < 0.001). CONCLUSION: Overexpression of AIB1 might provide a selective advantage for lymph node metastasis of lung ADC and serve as a useful biomarker for poor prognosis for NSCLC patients.
BACKGROUND: The amplified in breast cancer 1 (AIB1) gene has been considered to play an oncogenic role in humancancers, but its clinical/prognostic significance in non-small-cell lung cancer (NSCLC) is still unclear. PATIENTS AND METHODS: The methods of immunohistochemistry and FISH were utilized to examine protein expression and amplification of AIB1 in 230 informative surgically resected NSCLCs and in 30 samples of normal lung tissues. RESULTS: Overexpression and amplification of AIB1 were found in 48.3% and 8.2% of NSCLCs, respectively. AIB1 overexpression was associated with AIB1 gene amplification and cell proliferation but not related to estrogen receptor (ER)-alpha, ER-beta, progesterone receptor or androgen receptor status. A positive correlation between AIB1 overexpression and an ascending pathologic node stage in lung adenocarcinoma (ADC) was observed (P = 0.043). Univariate survival analysis demonstrated a significant association of AIB1 overexpression with shortened patient survival, especially for those with stage III disease (P < 0.001). Importantly, AIB1 expression was evaluated as the most significant predictor for survival in multivariate analysis (hazards ratio = 2.069, P < 0.001). CONCLUSION: Overexpression of AIB1 might provide a selective advantage for lymph node metastasis of lung ADC and serve as a useful biomarker for poor prognosis for NSCLCpatients.
Authors: Di Cai; David S Shames; Maria Gabriela Raso; Yang Xie; Young H Kim; Jonathan R Pollack; Luc Girard; James P Sullivan; Boning Gao; Michael Peyton; Meera Nanjundan; Lauren Byers; John Heymach; Gordon Mills; Adi F Gazdar; Ignacio Wistuba; Thomas Kodadek; John D Minna Journal: Cancer Res Date: 2010-07-27 Impact factor: 12.701
Authors: Bryan C Nikolai; Rainer B Lanz; Brian York; Subhamoy Dasgupta; Nicholas Mitsiades; Chad J Creighton; Anna Tsimelzon; Susan G Hilsenbeck; David M Lonard; Carolyn L Smith; Bert W O'Malley Journal: Cancer Res Date: 2016-02-01 Impact factor: 12.701